Evidence map›Paper›PMID 37675247›Full record

ReviewTherapeutic advances in gastroenterology2023

Update on the second-line treatment of

Chih-An Shih, Chang-Bih Shie, Wei-Chen Tai, Seng-Kee Chuah, Hsi-Chang Lee, Ping-I Hsu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Lack of follow-up inWorld journal of gastroenterology · 2026
    Article
  3. Article
  4. Therapeutic advances and future directions inFrontiers in microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Chih-An ShihDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Antai Medical Care Corporation, Antai Tian-Sheng Memorial Hospital, Pingtung County.
Chang-Bih ShieDivision of Gastroenterology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan.
Wei-Chen TaiDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, and Chang Gung University College of Medicine, Taoyuan.
Seng-Kee ChuahDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, and Chang Gung University College of Medicine, Taoyuan.ORCID https://orcid.org/0000-0002-8934-3223
Hsi-Chang LeeDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Renai Branch, Taipei City Hospital, 10, Section 4, Ren'ai Road, Da'an District 106, Taipei.
Ping-I HsuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, An Nan Hospital, China Medical University, No. 66, Sec. 2, Changhe Road., Annan Dist., Tainan City 70965.
Chang Gung University · TWChina Medical University · CNMeiho University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A standard bismuth quadruple therapy, a fluoroquinolone-containing triple (or quadruple) therapy or a proton pump inhibitor (PPI)-amoxicillin high-dose dual therapy has been recommended as a second-line treatment for

Indexed as

amoxicillin-levofloxacin quadruple therapybismuth quadruple therapyHelicobacter pylorihigh-dose dual therapysecond-line treatmenttetracycline-levofloxacin quadruple therapy

Identifiers

PMID37675247
PMCPMC10478561
OpenAlexW4386430665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.